Literature DB >> 1717818

Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts.

P Whiting1, R Schoepfer, J Lindstrom, T Priestley.   

Abstract

Previously, we purified the predominant subtype of brain nicotinic acetylcholine receptor (AChR), analyzed its structure, and found that it was composed of two kinds of subunit, with sequences encoded by cDNAs termed alpha 4 and beta 2. Here we express these cDNAs from chicken brain in stably transfected fibroblasts. We demonstrate by synthesis that these cDNAs encode subunit polypeptides of the expected sizes, which coassemble to form receptor macromolecules having the same size as native AChRs. Additionally, we demonstrate that the expressed AChRs exhibit the ligand-binding pharmacology of native brain AChRs and function as acetylcholine-gated ion channels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717818

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  31 in total

1.  Stable expression of mammalian type A gamma-aminobutyric acid receptors in mouse cells: demonstration of functional assembly of benzodiazepine-responsive sites.

Authors:  K L Hadingham; P C Harkness; R M McKernan; K Quirk; B Le Bourdellès; A L Horne; J A Kemp; E A Barnard; C I Ragan; P J Whiting
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

2.  Long-lasting enhancement of glutamatergic synaptic transmission by acetylcholine contrasts with response adaptation after exposure to low-level nicotine.

Authors:  R Girod; L W Role
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

3.  Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits.

Authors:  K J Elliott; S B Ellis; K J Berckhan; A Urrutia; L E Chavez-Noriega; E C Johnson; G Veliçelebi; M M Harpold
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 4.  Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels.

Authors:  A Devillers-Thiéry; J L Galzi; J L Eiselé; S Bertrand; D Bertrand; J P Changeux
Journal:  J Membr Biol       Date:  1993-11       Impact factor: 1.843

5.  Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells.

Authors:  N Le Novère; J P Changeux
Journal:  J Mol Evol       Date:  1995-02       Impact factor: 2.395

6.  Age-related changes in neuronal nicotinic acetylcholine receptor subunit alpha4 expression are modified by long-term nicotine administration.

Authors:  S W Rogers; L C Gahring; A C Collins; M Marks
Journal:  J Neurosci       Date:  1998-07-01       Impact factor: 6.167

7.  Two mutations linked to nocturnal frontal lobe epilepsy cause use-dependent potentiation of the nicotinic ACh response.

Authors:  A Figl; N Viseshakul; N Shafaee; J Forsayeth; B N Cohen
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

8.  Critical elements determining diversity in agonist binding and desensitization of neuronal nicotinic acetylcholine receptors.

Authors:  P J Corringer; S Bertrand; S Bohler; S J Edelstein; J P Changeux; D Bertrand
Journal:  J Neurosci       Date:  1998-01-15       Impact factor: 6.167

9.  Detection of functional nicotinic receptors blocked by alpha-bungarotoxin on PC12 cells and dependence of their expression on post-translational events.

Authors:  E M Blumenthal; W G Conroy; S J Romano; P D Kassner; D K Berg
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

10.  Rat neuronal nicotinic acetylcholine receptors containing alpha7 subunit: pharmacological properties of ligand binding and function.

Authors:  Yingxian Xiao; Galya R Abdrakhmanova; Maryna Baydyuk; Susan Hernandez; Kenneth J Kellar
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.